The European Medicines Agency concluded that the blood clotting should be included in the list of rare side effects caused by vaccine by Jansen company, which is the division of Johnson & Johnson. Press office of the EMA reported that on Tuesday.
"At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine", reads the message.
Eight messages of thromboembolic episodes were observed among more than 7,000,000 vaccinated people; all these cases occurred in people aged under 60; most of them were women. All episodes took place within three weeks after vaccination.
At that, the EMA added that the benefits of the use of vaccine continue to outweigh the risks.
"Healthcare professionals and people who will receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination", the EMA reiterates.